Chen, Hong-hua published the artcileEfficacy of manual reduction combined with betahistine mesylate in treatment of benign paroxysmal positional vertigo, SDS of cas: 54856-23-4, the publication is Xiandai Zhenduan Yu Zhiliao (2017), 28(7), 1235-1236, database is CAplus.
To explore the efficacy of manual reduction combined with drugs in the treatment of 60 cases of benign paroxysmal positional vertigo. Patients who were diagnosed with benign paroxysmal positional vertigo in our hospital from Feb. 2013 to Jan. 2015 were collected and randomly divided into a study group and a control group. The basic treatment of the two groups was manual reduction, and the study group was treated with betahistine mesylate tablets. The therapeutic effects of the two groups were compared for benign paroxysmal positional vertigo. The two groups were scored by the Vertigo Disorder Rating Scale before and after treatment. The therapeutic effects of the study group and the control group for benign paroxysmal positional vertigo were 100% and 66.7%, resp., and there was a difference (P < 0.05). The study group and the control group had no difference in the scores of the Vertigo Disorder Rating Scale before treatment (P > 0.05). There was a difference in the scores of the vertigo disorder rating scale between the study group and the control group after treatment (P < 0.05). This article believes that manual reduction combined with drugs has a definite effect in the treatment of benign paroxysmal positional vertigo and can significantly improve the symptoms of patients.
Xiandai Zhenduan Yu Zhiliao published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, SDS of cas: 54856-23-4.
Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem